Public-Private Partnerships as Driving Forces for Innovative …/media/Files/Activity... ·...
8
Public-Private Partnerships as Driving Forces for Innovative Treatments and Research Policies 11 th July 2016, NASEM, Washington DC Nigel Hughes, Scientific Director, RMEDS Quantitative Sciences, Janssen R&D The presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participant individually and, unless expressly stated to the contrary, are not the opinion or position of Janssen or its affiliates.
Transcript of Public-Private Partnerships as Driving Forces for Innovative …/media/Files/Activity... ·...
Public-Private Partnerships as Driving Forces for Innovative Treatments and Research Policies
11th July 2016, NASEM, Washington DC
Nigel Hughes, Scientific Director, RMEDS
Quantitative Sciences, Janssen R&D
The presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participant individually and, unless expressly stated to the contrary, are
not the opinion or position of Janssen or its affiliates.
2
Agenda
PPP in EU: Innovative Medicines Initiative
– EMIF: European Medical Information Framework
– EHR4CR/InSite: Electronic Health Records 4 Clinical Research
National Institutes of Health: Accelerating Medicines
Partnership
What have we learned? What have we achieved, what is our legacy?
Innovative Medicines Initiative
3
IMI: a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.
4
www.emif.eu; accessed 06/07/16
European Medical Information Framework: EMIF
Population & Cohort Data: Lifecycle
5 5 5
Hospital Data: Clinical Development
National Institutes of Health Accelerating Medicines Partnership
6 https://www.nih.gov/research-training/accelerating-medicines-partnership-amp; accessed 06/07/16
Study Data: Translational
What have we learned? It’s complicated….
7
• It’s all about people, not just data, and aligning agendas is critical to success
• Ultimately you need a quid pro quo between stakeholders
• Optimal project management of large-scale programmes paramount
• Federation of data sources with harmonisation is a necessary foundation – access!
• There is a technology solution for most problems – what is good enough?
• Do not underestimate the time taken/required in these programmes – latency!
What have we achieved, what is our legacy? A means to an end….
8
• Pre-competitive collaboration of Industry
• Alignment of Industry with Academia R&D for mutual scientific outputs
• Harmonisation of relevant data sources & potential portals for future work
• We have striven to achieve innovation in translational biological research, incorporating phenotype and genotype insights for biomarker and therapeutic target development in concerning chronic diseases for our society
• Most importantly, we have opened Industry and Academia to collaboration models and recognition that the future of therapeutic R&D cannot be conducted in isolation
